Bailard’s Tectonic Therapeutic TECX Stock Holding History

Bailard’s Portfolio TECX Stock Details TECX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,791	Closed	-$45.5K	–	796
2023 Q1	$45.5K	Buy	3,791 +1,642	+76%	+$22.9K	﹤0.01%	697
2022 Q4	$18.4K	Buy	+2,149	New	+$18.9K	﹤0.01%	701

Other funds holding TECX

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bailard's TECX Position: Q2 2023 in Review

Bailard sold out of Tectonic Therapeutic (TECX) in Q2 2023, closing a stake of 3,791 shares — an estimated $45.5K sold.

Bailard first reported a position in TECX in Q4 2022 and held it in 2 quarters. The position peaked at $45.5K in Q1 2023. 40 funds tracked by Wall St. Rank hold TECX as of Q2 2023.

Bailard reported no remaining Tectonic Therapeutic position as of Q2 2023 after selling out during the quarter.
Bailard sold 3,791 Tectonic Therapeutic shares in Q2 2023, an estimated $45.5K.
Bailard first reported a position in Tectonic Therapeutic in Q4 2022 and held it in 2 quarters.
Bailard's Tectonic Therapeutic position peaked at $45.5K in Q1 2023.
40 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q2 2023.

Based on Bailard's 13F filing for Q2 2023, filed 20 Jul 2023.